Comparison of Breast Cancer-Related Lymphedema (Upper Limb Swelling) Prevalence Estimated Using Objective and Subjective Criteria and Relationship with Quality of Life
Table 1
Participant characteristics.
Participant characteristics ( = number)
MSTa ( = 577)
LBCQb ( = 410)
Perometry ( = 389)
Complete data for MSTa, LBCQb, and perometry ( = 341)
Age: mean (SDc)
62.21 (10.03)
60.99 (9.97)
60.97 (9.95)
60.49 (9.99)
Months since treatment: median (range)
54 (0–360) ( = 575 with data)
50 (0–360) ( = 409 with data)
51 (0–360) ( = 387 with data)
49 (0–360) ( = 341 with data)
Wide local excision: (%d)
412 (72.3% of 570)
292 (72.0% of 406)
269 (69.9% of 385)
238 (70.4% of 338)
Mastectomy: (%d)
156 (27.4% of 568)
112 (27.8% of 404)
114 (29.8% of 384)
100 (29.6% of 337)
Axillary surgerye: (%d)
292 (59.3% of 493)
218 (61.5% of 354)
231 (59.6% of 387)
179 (60.4% of 297)
Radiotherapy to the breast: (%d)
474 (82.5% of 575)
336 (82.2% of 409)
317 (81.7% of 388)
278 (81.8% of 340)
Radiotherapy to the axilla: (%d)
139 (24.3% of 574)
102 (25.1% of 408)
94 (24.4% of 387)
81 (23.8% of 339)
aMST: Morbidity Screening Tool.
bLBCQ: Lymphedema and Breast Cancer Questionnaire.
cSD: standard deviation.
d% frequency of number of participants with data for participant characteristic.
eAxillary surgery includes lymph node clearance, four-node sampling, and sentinel lymph node biopsy.
